David Spirk
Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE).
Sudano I, Mach F, Moccetti T, Burkard T, Fahe C, Delabays A, Rickli H, Keller P, Dopheide J, Bodenmann S, Fiolka T, Ehret G, Spirk D. Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE). Front Cardiovasc Med 2022; 9:953040.
15.07.2022Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE).
15.07.2022Front Cardiovasc Med 2022; 9:953040
Sudano Isabella, Mach François, Moccetti Tiziano, Burkard Thilo, Fahe Christian, Delabays Alain, Rickli Hans, Keller Pierre-Fréderic, Dopheide Jörn, Bodenmann Sereina, Fiolka Tom, Ehret Georg, Spirk David
Regional differences of glycaemic control in patients with type 2 diabetes mellitus in Switzerland: a national cross-sectional survey
Gerber P, Spirk D, Brändle M, Thoenes M, Lehmann R, Keller U. Regional differences of glycaemic control in patients with type 2 diabetes mellitus in Switzerland: a national cross-sectional survey. Swiss Med Wkly 2011; 141:w13218.
07.07.2011Regional differences of glycaemic control in patients with type 2 diabetes mellitus in Switzerland: a national cross-sectional survey
07.07.2011Swiss Med Wkly 2011; 141:w13218
Gerber Philipp Andreas, Spirk David, Brändle Michael, Thoenes Martin, Lehmann Roger, Keller Ulrich